touchNEUROLOGY met up with Prof. Bernhard Hemmer (TUM-Klinikum rechts der Isar, Munich, Germany) to discuss the primary data from the phase III Antelope study, investigating proposed natalizumab biosimilar PB006 in relapsing remitting multiple sclerosis. The abstract entitled: ‘Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: primary […]

touchNEUROLOGY met with Prof. Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss a subgroup analysis from a phase 3 safety study investigating the use of diazepam nasal spray in patients with seizure clusters concomitantly receiving clobazam. Diazepam nasal spray is an FDA-approved nasal spray version of diazepam, indicated for the treatment of acute, […]

It was a great pleasure to meet with both Dr Monica Ferrer Socorro (NYU Langone Health, New York City, NY, USA) and Prof. Jacqueline French (NYU Grossman School of Medicine, New York City, NY, USA) to discuss a retrospective analysis investigating focal epilepsy, its clinical presentation in adolescents, highlighting disproportionate delay to diagnosis experienced by […]

We had the pleasure of meeting with Dr William E. Rosenfeld, MD (Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, MO, USA). Dr Rosenfeld discusses the use of cenobamate as an antiseizure medication for the treatment of adults with focal seizures. Here he discusses a number of posters presented at AES 2021 from […]

Postpartum depression (PPD) is an important mental health problem that is associated with maternal distress and poor maternal–fetal bonding. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) now classifies PPD as major depressive disorder (MDD), with peripartum onset.1 The distinction ‘with peripartum onset’ is new in DSM-5 and is important, as 50% of ‘postpartum’ major […]

Migraine is a neurologic disease characterized by recurrent attacks of head pain and symptoms such as nausea, photophobia and phonophobia, which last hours to days.1 Attacks themselves can be disabling, and due to the often unpredictable and unavoidable nature of the attacks, the disease itself accounts for substantial disability.2 In fact, migraine affects 12% of the global […]

Ischaemic stroke may occur due to several potential mechanisms. Mechanisms are classically described as large artery atherosclerosis, small-vessel occlusion, cardioembolism, stroke of other determined aetiology (i.e. vasculitis, genetic disorder, etc.) and stroke of undetermined aetiology. Historically, the definition of stroke of undetermined aetiology has included strokes with multiple potential mechanisms, as well as those with […]

Parkinson’s disease (PD) is a progressive, neurodegenerative movement disorder and the second most common neurodegenerative disorder in the United States.¹ In 2020, approximately 930,000 people in the United States aged 45 years and older developed the disease, and this number is expected to rise to 1,238,000 by 2030.2 The typical age of onset is around 60 years, […]